People · Operator
Named in public records as an officer, director or promoter · active 2010–2012 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Axion BioSystems, Inc. | — | Biotechnology | Series A | $20.6M | $289.2M | 2010 |
Stephen J. DeWeerth at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Stephen J. DeWeerth on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mark Allen | 1 | 9 |
| James Ross | 1 | 4 |
| Greg Dane | 1 | 2 |
| Stephen DeWeerth | 1 | 1 |
| Edgar Brown | 1 | 1 |
| Swaminathan Rajaraman | 1 | 1 |
| Swaminathan J. Rajaraman | 1 | 1 |
| Edgar J. Brown | 1 | 1 |
| Glenn A. Epstein | 1 | 1 |
| James J. Ross | 1 | 1 |
| Mark J. Allen | 1 | 1 |
| GLENN J. EPSTEIN | 1 | 1 |
| DAVID J. GIBSON | 1 | 1 |
| JAY J. TEICH | 1 | 1 |
| MICHELLE J. JARRARD | 1 | 1 |
| Thomas J. O'Brien | 1 | 1 |
| Julian A. Bragg | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.